2025 KSPNO Guideline: Diagnosis and Treatment of Medulloblastoma
KSPNO = Korean Society of Pediatric Neuro-Oncology Applicable population: Pediatric and adolescent medulloblastoma (age ≥3 years; separate considerations for infants <3 years old). Histological and molecular classification is the core of risk stratification. Histologic subtypes: Classic medulloblastoma, desmoplastic/nodular medulloblastoma (DNMB), large‑cell/anaplastic medulloblastoma (LC/A MB). Molecular subgroups (consensus): WNT‑activated, SHH‑activated (TP53 wild‑type / TP53 mutant), Group 3, Group 4.
Preface
Medulloblastoma is the most common malignant embryonal brain tumor in children, arising in the cerebellar vermis and cerebellar hemispheres. Outcomes vary dramatically across molecular subgroups. This guideline was developed by the Korean Society of Pediatric Neuro‑Oncology (KSPNO), based on domestic cohort data and international trials, to standardize staging, molecular testing, risk stratification, surgery, craniospinal irradiation, chemotherapy, supportive care, surveillance, and management of recurrent disease.
1. Initial Workup and Staging
1.1 Pre‑operative evaluation
-
Brain MRI with and without contrast (including sagittal/coronal sequences); spinal MRI with contrast within 21 days after surgery (to avoid post‑surgical false‑positive leptomeningeal signal).
-
Baseline ophthalmologic exam, audiometry, neurocognitive baseline assessment.
-
Laboratory: CBC, renal and hepatic function, baseline hearing test (audiogram).
-
Lumbar cerebrospinal fluid (CSF) cytology for staging; CSF sampling is recommended at least 10–14 days after surgery to avoid surgical contamination.
-
Germline genetic counseling and testing for patients with SHH‑TP53 mutant, multiple primary tumors, or family history of cancer predisposition syndromes (Li‑Fraumeni, Gorlin syndrome, APC‑associated polyposis).
1.2 Staging system (Chang staging)
-
M0: No metastatic disease; CSF cytology negative, spinal MRI negative
-
M1: Tumor cells in CSF only, no macroscopic spinal disease
-
M2: Intracranial metastatic nodules
-
M3: Spinal leptomeningeal metastases
-
M4: Extraneural metastasis (rare)
1.3 Mandatory molecular testing
All medulloblastoma specimens require molecular subgroup assignment:
-
WNT‑activated: Excellent prognosis; CTNNB1 mutation; monosomy 6 is characteristic.
-
SHH‑activated: Further stratified by TP53 status. SHH TP53‑wild type: intermediate prognosis; SHH TP53‑mutant: poor prognosis.
-
Group 3: High risk, high metastatic rate at diagnosis; MYC amplification is a high‑risk feature.
-
Group 4: Most common subgroup; frequent isochromosome 17q; metastatic disease is common but prognosis is better than Group 3 MYC‑amplified.
Recommendation: DNA methylation profiling is preferred for definitive subgroup classification when available.
2. Risk Stratification (for patients ≥3 years old, post‑surgical)
-
Standard‑risk
-
WNT‑activated (any resection, M0)
-
Non‑WNT: M0, ≥1.5 cm² residual tumor on postoperative MRI, non‑LC/A histology, no MYC amplification
-
High‑risk
-
M+ (M1–M3)
-
Residual tumor ≥1.5 cm²
-
Large‑cell/anaplastic histology
-
SHH TP53‑mutant
-
Group 3 with MYC amplification
-
Infant subgroup (<3 years old) Craniospinal irradiation is deferred whenever possible; chemotherapy‑first strategy is adopted to reduce radiation‑related neurocognitive injury.
3. Surgical Management
-
Gross total resection (GTR) is the primary goal; maximal safe resection.
-
Second‑look surgery: Consider if residual tumor >1.5 cm² and the lesion is surgically accessible, before initiating radiotherapy.
-
Avoid aggressive brainstem dissection; neurological function takes priority.
-
Perioperative complications: Posterior fossa syndrome (cerebellar mutism syndrome) must be monitored; early rehabilitation and supportive care.
-
Biopsy only: For patients with widespread disseminated disease not suitable for upfront resection.
4. Upfront Adjuvant Therapy (Age ≥3 years)
4.1 Standard‑risk medulloblastoma
-
Craniospinal irradiation (CSI): Reduced dose CSI 23.4 Gy, plus posterior fossa boost to 54–55.8 Gy.
-
Concurrent chemotherapy: Vincristine during radiation.
-
Adjuvant chemotherapy after radiation: CCNU, cisplatin, vincristine (standard backbone).
-
WNT subgroup special note: Several trials support further dose reduction of CSI in selected WNT M0 patients; decision made by neuro‑oncology MDT.
4.2 High‑risk medulloblastoma
-
CSI: 36 Gy, posterior fossa/tumor bed boost to 54–55.8 Gy.
-
Concurrent vincristine.
-
Adjuvant chemotherapy: Cisplatin, CCNU, vincristine; alternative regimens include cyclophosphamide‑based schedules.
-
MYC‑amplified Group 3 / SHH TP53‑mutant: Consider high‑dose chemotherapy with autologous stem cell rescue (HDCT‑ASCR) in specialized centers.
4.3 Children <3 years old
-
Delay or omit craniospinal radiation.
-
Induction chemotherapy followed by maintenance chemotherapy.
-
Local conformal radiation only for poor response or residual progressive disease, as late salvage.
-
HDCT‑ASCR may be used for high‑risk infant medulloblastoma.
5. Radiotherapy Technical Principles
-
CSI: Volumetric technique (IMRT / VMAT / proton therapy preferred). Proton radiotherapy is strongly recommended for pediatric patients to reduce off‑target dose to growing organs, hypothalamus, cochlea, heart and lungs.
-
Boost volume: Tumor bed plus residual disease, not the whole posterior fossa in modern protocols.
-
Cochlear dose constraints are critical to reduce cisplatin‑related hearing loss.
-
Re‑irradiation: Reserved for localized recurrent disease only, highly individualized in specialized centers.
6. Supportive Care
-
Ototoxicity monitoring: Serial audiometry. Cisplatin dose modification or discontinuation for progressive hearing loss. Sodium thiosulfate may be considered for otoprotection per institutional protocol.
-
Endocrine surveillance: Growth hormone, thyroid, adrenal, pubertal function screening after CSI.
-
Neurocognitive and educational support: Long‑term follow‑up of IQ, attention, memory, academic performance.
-
Posterior fossa mutism syndrome: Speech therapy, occupational therapy, psychiatric support.
-
Chemotherapy complications: Cisplatin renal monitoring, CCNU myelosuppression, vincristine peripheral neuropathy.
-
Late‑effect surveillance: Second neoplasms (especially SHH subgroup / germline TP53).
7. Surveillance Schedule after Completion of Upfront Therapy
-
Brain + spine MRI with contrast
-
Years 1–2: Every 3 months
-
Year 3: Every 4 months
-
Years 4–5: Every 6 months
-
After 5 years: Annual brain MRI; spinal MRI only if symptoms or abnormal brain imaging
-
Audiometry, endocrine panel, neuropsychological assessment annually for at least 5 years.
-
CSF cytology is not routine surveillance; only for suspicious imaging or symptoms.
8. Recurrent Medulloblastoma
-
Re‑staging: Brain + spine MRI, CSF cytology, repeat molecular profiling (liquid biopsy or re‑biopsy if feasible).
-
Local isolated recurrence:
-
If no prior proton / high‑dose focal radiation: Re‑irradiation (SBRT / focal proton boost) + chemotherapy.
-
Resectable localized recurrence: Reoperation followed by adjuvant therapy.
-
Disseminated recurrent disease:
-
HDCT + autologous stem cell rescue for eligible patients.
-
Targeted agents: SMO inhibitors for SHH subgroup (SMO‑mutant, non‑PTCH1 loss).
-
Immunotherapy: Clinical trial priority; single‑agent checkpoint inhibitors have limited efficacy in unselected medulloblastoma.
-
All recurrent patients should be offered clinical trial enrollment whenever possible.
9. Special Considerations
-
SHH subgroup: SMO inhibitors (sonidegib, vismodegib) are approved for relapsed SHH medulloblastoma; monitor for musculoskeletal toxicity, growth plate injury in young children.
-
WNT subgroup: Excellent prognosis; avoid overtreatment; MDT review before radiation dose reduction.
-
Group 3 MYC amplified: Poor outcome; frontline HDCT‑ASCR is often considered.
-
Hereditary tumor predisposition: Genetic counseling for all SHH TP53‑mutant patients.
-
Adolescent and young adult (AYA): Balance pediatric and adult neuro‑oncology approaches; fertility preservation before chemotherapy/radiation.
10. 2025 KSPNO Key Updates
-
DNA methylation profiling recommended as the gold standard for molecular subgrouping, replacing immunohistochemistry‑only classification.
-
Formal recommendation for proton therapy for CSI in standard‑risk and high‑risk children.
-
Refined criteria for WNT subgroup de‑escalation of craniospinal radiation (only in M0, complete resection, no high‑risk features).
-
HDCT‑ASCR position strengthened for frontline MYC‑amplified Group 3 and SHH TP53‑mutant medulloblastoma.
-
SMO inhibitor sequencing algorithm updated for relapsed SHH medulloblastoma; notes on growth toxicity in skeletally immature patients.
-
Standardized long‑term late‑effect surveillance checklist for Korean pediatric survivors.
Citation
Korean Society of Pediatric Neuro‑Oncology (KSPNO). 2025 KSPNO Guideline: Diagnosis and Treatment of Medulloblastoma. Journal of Korean Pediatric Neuro‑Oncology, 2025, 12(1): 1–32.